CD8A and neoplasm: In melanoma cancer treatments, the response to pembrolizumab is associated with a higher number of CD8+, PD-1+, and PD-L1+ cells within tumor tissue, suggesting the need for reinvigorating pre-existing T cells in the tumor by inhibiting the PD-1/PD-L1 signaling cascade in TME [16].